VRBPAC

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) evaluated Moderna’s COVID-19 vaccine as highly effective with a favorable safety profile, based on interim data from an ongoing phase 3 trial. The panel acknowledged that further studies will be required post issuance of an Emergency Use Authorization (EUA) to collect additional data on
0 Comments